BioGend
博晟生醫股份有限公司
BioGend: RevoCart (BiG-012 / BiG-009; medical device) — Taiwan medical device license 006689 granted; not a drug trial phase. As of 2026-11-01.
Pipeline and products
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| RevoCart (BiG-012 / BiG-009; medical device) | — | Taiwan medical device license 006689 granted; not a drug trial phase | Articular cartilage repair | — | — | Company disclosure |
| BiG-001 (OIF / beta-TCP; combination device) | — | Feasibility study completed; Taiwan pivotal trial application planned in 2026, initiation unconfirmed | Bone defect repair including open tibial fractures | — | — | Company disclosure |
| BiG-006 (OIF / beta-TCP; combination device) | — | Preclinical evaluation ongoing; not a drug clinical phase | Lumbar interbody fusion | — | — | Company disclosure |
Key events
Related Drugnews articles
No related articles in this language.